These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8457470)

  • 1. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon.
    Meseri A; Delwail V; Brizard A; Lecron JC; Pelletier D; Guilhot F; Tanzer J; Goube de Laforest P
    Br J Haematol; 1993 Feb; 83(2):218-22. PubMed ID: 8457470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
    Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
    Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
    Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
    Verfaillie C; Miller W; Kay N; McGlave P
    Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
    Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
    Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).
    Pawelec G; Schneider E; Ehninger G; Rehbein A; Schmidt H
    Cancer Immunol Immunother; 1989; 29(1):63-6. PubMed ID: 2785001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
    Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
    Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
    Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
    Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
    Mackinnon S; Bungey J; Chase A; Paulsen W; Hows JM; Goldman JM
    Br J Haematol; 1991 Jan; 77(1):60-5. PubMed ID: 1998598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
    Cervantes F; Miller JS; McGlave PB
    Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological effects of interferon-alpha on chronic myelogenous leukemia.
    de Castro FA; Palma PV; Morais FR; Simões BP; Carvalho PV; Ismael SJ; Lima CP; Voltarelli JC
    Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
    Bergeron D; Ouellette MJ; Lambert RD
    J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.